Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Peginterferon Alfa-2a on the Relapse Rate of the Subjects With Hepatocellular Carcinoma Who Have Been Treated by Resection

NCT03253250 is registered in ClinicalTrials.gov with Huashan Hospital as lead sponsor.

NCT NCT03253250
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03253250 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Multicenter, Open-label, Exploratory Study of Utilizing of Peginterferon Alfa-2a on the Relapse Rate of the Subjects With Hepatocellular Carcinoma Who Have Been Treated by Resection
Lead sponsor
Huashan Hospital
Phase
Phase 4
Overall status
Unknown status
Start date
September 1, 2017
Completion date
December 31, 2019
Enrollment
432 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b, hepatic carcinoma